Testing vonoprazan to prevent delayed kidney function after transplant
Part of Kidney & urinary clinical trials.
This trial tests whether a medicine called vonoprazan fumarate can help prevent delayed kidney function after a first kidney transplant from a deceased donor. It is for people who are ready to follow standard post-transplant care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and getting your first kidney transplant.
- The kidney will come from a deceased donor (someone who has died).
- You haven't taken any acid-blocking medication (like vonoprazan) in the last month.
- You are willing to take the standard anti-rejection medicines after transplant.
- You don't have severe liver disease or take certain other medicines that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether treprostinil (Remodulin®) can reduce injury to a transplanted kidney right after surgery. If it works and is safe, it may help improve outcomes for people receiving a deceased-donor kidney transplant.
This trial tests whether giving a diuretic (a medication that helps flush fluids) during kidney transplant surgery helps a deceased-donor kidney start working sooner after the procedure.
This study tests an investigational medicine (ravulizumab) given through a vein to see if it can prevent delayed graft function—meaning the new kidney takes longer to start working—after a high-risk kidney transplant. It is for adults on dialysis who are getting a kidney from a donor whose heart stopped or who is considered high-risk.
This Phase 1/2 trial tests how safe AT 1501 is and how it works in people getting their first kidney transplant. It aims to improve transplant outcomes by targeting the immune system, while carefully watching for side effects and immune compatibility issues.
This study tests whether a medicine called finerenone can help protect kidney transplants from further damage. People who have had a kidney transplant and have protein in their urine may benefit from this treatment.
This study follows adults who previously received vonsetamig in an earlier study and then got a kidney transplant while enrolled. It mainly looks at what happens after the transplant and helps doctors understand outcomes over time.
Hear when a new Delayed Graft Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.